Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

RedHill Biopharma (RDHL) Net Margin (2016 - 2023)

RedHill Biopharma has reported Net Margin over the past 12 years, most recently at 3280.68% for Q2 2023.

  • Quarterly Net Margin rose 324467.0% to 3280.68% in Q2 2023 from the year-ago period, while the trailing twelve-month figure was 111.91% through Jun 2023, up 3782.0% year-over-year, with the annual reading at 2675.17% for FY2025, 277797.0% up from the prior year.
  • Net Margin was 3280.68% for Q2 2023 at RedHill Biopharma, up from 220.03% in the prior quarter.
  • Over five years, Net Margin peaked at 3280.68% in Q2 2023 and troughed at 658.08% in Q4 2021.
  • The 5-year median for Net Margin is 67.81% (2020), against an average of 368.88%.
  • Year-over-year, Net Margin plummeted -149215bps in 2021 and then surged 324467bps in 2023.
  • A 5-year view of Net Margin shows it stood at 744.47% in 2019, then crashed by -91bps to 70.29% in 2020, then plummeted by -1036bps to 658.08% in 2021, then increased by 17bps to 543.22% in 2022, then skyrocketed by 704bps to 3280.68% in 2023.
  • Per Business Quant, the three most recent readings for RDHL's Net Margin are 3280.68% (Q2 2023), 220.03% (Q1 2023), and 543.22% (Q4 2022).